Evidence map›Paper›PMID 27558431›Full record

ArticleJournal of virology2016

Exploitation of Interleukin-10 (IL-10) Signaling Pathways: Alternate Roles of Viral and Cellular IL-10 in Rhesus Cytomegalovirus Infection.

Meghan K Eberhardt, Ashlesha Deshpande, Joseph Fike, Rebecca Short, Kimberli A Schmidt, Shelley A Blozis, Mark R Walter, Peter A Barry

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Human Cytomegalovirus Interleukin 10 Homologs: Facing the Immune System.Frontiers in cellular and infection microbiology · 2020
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. IL-10: A Multifunctional Cytokine in Viral Infections.Journal of immunology research · 2017
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Meghan K EberhardtCenter for Comparative Medicine, California National Primate Research Center, Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA.
Ashlesha DeshpandeDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Joseph FikeCenter for Comparative Medicine, California National Primate Research Center, Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA.
Rebecca ShortCenter for Comparative Medicine, California National Primate Research Center, Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA.
Kimberli A SchmidtCenter for Comparative Medicine, California National Primate Research Center, Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA.
Shelley A BlozisDepartment of Psychology, University of California, Davis, Davis, California, USA.
Mark R WalterDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA walter@uab.edu pabarry@ucdavis.edu.
Peter A BarryCenter for Comparative Medicine, California National Primate Research Center, Department of Pathology and Laboratory Medicine, University of California, Davis, Davis, California, USA walter@uab.edu pabarry@ucdavis.edu.
University of California, Davis · USUniversity of Alabama at Birmingham · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10R01AI049342 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2002 to 2017
$6.9M
STRUCTURE STUDIES ON PROTEINS THAT MODULATE IL-10 ACTIONR01AI047300 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WALTER, MARK R · 2001 to 2011
$3.4M
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and ReinfectionR01AI097629 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BARRY, PETER A, WALTER, MARK R · 2012 to 2016
$3.1M
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA093373NIAID NIH HHS R01 AI047300NIAID NIH HHS R01 AI049342NIAID NIH HHS R01 AI097629NIH HHS P51 OD011107
6 · The paper itself

Abstract

There is accumulating evidence that the viral interleukin-10 (vIL-10) ortholog of both human and rhesus cytomegalovirus (HCMV and RhCMV, respectively) suppresses the functionality of cell types that are critical to contain virus dissemination and help shape long-term immunity during the earliest virus-host interactions. In particular, exposure of macrophages, peripheral blood mononuclear cells, monocyte-derived dendritic cells, and plasmacytoid dendritic cells to vIL-10 suppresses multiple effector functions including, notably, those that link innate and adaptive immune responses. Further, vaccination of RhCMV-uninfected rhesus macaques with nonfunctional forms of RhCMV vIL-10 greatly restricted parameters of RhCMV infection following RhCMV challenge of the vaccinees. Vaccinees exhibited significantly reduced shedding of RhCMV in saliva and urine following RhCMV challenge compared to shedding in unvaccinated controls. Based on the evidence that vIL-10 is critical during acute infection, the role of vIL-10 during persistent infection was analyzed in rhesus macaques infected long term with RhCMV to determine whether postinfection vaccination against vIL-10 could change the virus-host balance. RhCMV-seropositive macaques, which shed RhCMV in saliva, were vaccinated with nonfunctional RhCMV vIL-10, and shedding levels of RhCMV in saliva were evaluated. Following robust increases in vIL-10-binding and vIL-10-neutralizing antibodies, shedding levels of RhCMV modestly declined, consistent with the interpretation that vIL-10 may play a functional role during persistent infection. However, a more significant association was observed between the levels of cellular IL-10 secreted in peripheral blood mononuclear cells exposed to RhCMV antigens and shedding of RhCMV in saliva. This result implies that RhCMV persistence is associated with the induction of cellular IL-10 receptor-mediated signaling pathways. IMPORTANCE: Human health is adversely impacted by viruses that establish lifelong infections that are often accompanied with increased morbidity and mortality (e.g., infections with HIV, hepatitis C virus, or human cytomegalovirus). A longstanding but unfulfilled goal has been to develop postinfection vaccine strategies that could "reboot" the immune system of an infected individual in ways that would enable the infected host to develop immune responses that clear reservoirs of persistent virus infection, effectively curing the host of infection. This concept was evaluated in rhesus macaques infected long term with rhesus cytomegalovirus by repeatedly immunizing infected animals with nonfunctional versions of the rhesus cytomegalovirus-encoded viral interleukin-10 immune-modulating protein. Following vaccine-mediated boosting of antibody titers to viral interleukin-10, there was modest evidence for increased immunological control of the virus following vaccination. More significantly, data were also obtained that indicated that rhesus cytomegalovirus is able to persist due to upregulation of the cellular interleukin-10 signaling pathway.

Indexed as

AnimalsCytomegalovirusCytomegalovirus InfectionsHost-Pathogen InteractionsImmunization, SecondaryInterleukin-10Leukocytes, MononuclearMacaca mulattaSignal TransductionVaccinationViral ProteinsVirus SheddingInterleukin-10Viral Proteins

Identifiers

PMID27558431
PMCPMC5068540
OpenAlexW2509048140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.